[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostate-specific-antigen\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostate-specific-antigen":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,73,101,129,156],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":43,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100649333","prostate-cancer-risk-calculator-for-actionable-clinical-decision-making-in-nigeria-100649333",false,"NCT07733440","PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria","Clinical Risk Calculator Validation and Implementation to Optimize Prostate Cancer Early Detection in Nigeria","PROACT","Inclusion Criteria:\n\n1. Training - Eligible primary care providers (for the training surveys) will be healthcare practitioners at community-level hospitals.\n2. Supported Risk Assessment\n\n(i) Eligible key informants will be eligible primary care providers who were trained and implemented the supported risk assessment and the targeted population of patient participants who received the supported risk assessment.\n\n(ii) Eligible patient participants (for the collection of observation data) will be the target population of adult males 40 - 79 years accessing provider services.\n\nExclusion Criteria:\n\n\\-",true,"MALE","18 Years",{"count":21,"type":22},89,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is a pilot trial that builds on findings from the validation of prostate cancer risk calculators in Nigerian men. The goal of the overall study is to improve the early detection of prostate cancer in a high-risk population.\n\nThe main questions the validation study aims to answer are:\n\n1. How accurately do existing prostate cancer risk calculators identify Nigerian men with clinically significant prostate cancer?\n2. Will a new risk calculator designed for Nigerian men more accurately identify those with clinically significant prostate cancer?\n\nThe main questions the intervention study aims to answer is:\n\nWill the primary care provider-facing risk calculator be feasible and acceptable for primary care providers to implement?\n\nThe intervention trial will be piloted among participants in community-level hospitals in order to primarily assess implementation outcomes",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42],"Prostate Cancer","Risk Assessment","Clinical Decision Support Systems","Predictive Value of Tests","Models","Algorithms","Evidence-Based Practice","Implementation Research","Community Health Services","Primary Health Care","Biomarker","Prostate Specific Antigen","Global Health","Africa","Nigeria",[44,45,46,47,48,49,50,51,52,53,54,55,41,56,57,58,59,42],"Prostate cancer","early detection","prostate cancer screening","early diagnosis","prostate specific antigen","risk calculator","risk prediction model","diagnostic accuracy","validation","prostate biopsy","primary care","implementation science","precision prevention","clinically significant prostate cancer","clinical prediction model","community oncology","NOT_YET_RECRUITING","2026-07-24",{"date":63,"type":64},"2026-07-29","ACTUAL",{"date":66,"type":22},"2029-03",{"date":68,"type":22},"2029-08",{"name":70,"class":71},"Ahmadu Bello University","OTHER",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100582403","flotufolastat-f-18-pet-in-men-with-very-low-psa-recurrence-100582403","NCT06862856","Flotufolastat F 18 PET in Men With Very Low PSA Recurrence","A Prospective Study of Flotufolastat F 18 Positron Emission Tomography in Men With Very Low Prostate Specific Antigen Recurrence","Inclusion Criteria:\n\n* Participants must have a history of localized histologically confirmed adenocarcinoma of the prostate and have received radical prostatectomy (RP) with curative intent.\n* Participants must have measurable disease, defined as a non-zero PSA value post-RP that is concerning for biochemically recurrent or persistent disease, is ≤0.20 ng\u002FmL, and obtained within 60 days of PET\u002FCT.\n* At least 6 weeks must have elapsed after RP. If previously taking ADT, it should have been discontinued at least 16 weeks prior to PET.\n* Participants with a clinical flotufolastat F 18 PSMA PET\u002FCT scan prescribed as part of the standard of care management.\n* Age ≥18 years.\n* Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants currently receiving ADT (defined as surgical orchidectomy; luteinizing hormone-releasing hormone \\[LHRH\\] agonist alone \\[continuous or intermittent\\]; LHRH antagonist alone \\[continuous or intermittent\\]; administration or use of a first or second generation anti-androgen alone or in combination with an LHRH agonist\u002Fantagonist).\n* Participants who are receiving any other investigational agents for this condition within five biological half-lives prior to administration of flotufolastat F 18.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to flotufolastat F 18 or other agents used in study.\n* Participants receiving any of the following substances will be considered ineligible: x-ray contrast agent \\\u003C24 hours prior to the flotufolastat F 18 PET and any other PET imaging agent within 24 hours or 10 half-lives, whichever is longer, prior to the flotufolastat F 18 PET\u002FCT. As part of the enrollment\u002Finformed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.",{"count":81,"type":22},50,"OBSERVATIONAL","The purpose of this study is to assess detection rate of flotufolastat F 18 positron emission tomography (PET) for low prostate specific antigen (PSA) recurrence of prostate cancer (PC) following radical prostatectomy.",[85,39],"Prostate Cancer (Adenocarcinoma)",[87,88,89],"flotufolastat F 18 positron emission tomography","low prostate specific antigen recurrence","prostate cancer","RECRUITING","2026-05-13",{"date":93,"type":64},"2026-05-15",{"date":95,"type":64},"2025-05-20",{"date":97,"type":22},"2026-12-01",{"name":99,"class":71},"Massachusetts General Hospital",2,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":108,"targetDuration":110,"studyType":82,"phases":4,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":72},"100632684","prognostic-value-of-early-postoperative-prostate-specific-antigen-for-oncological-outcomes-after-radical-prostatectomy-100632684","NCT07516886","Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy","PPSARP","Inclusion Criteria:\n\n* Patient is an adult biological male.\n* Patient has morphologically confirmed and untreated prostate cancer.\n* Patient who will be treated with open, laparoscopic or robot-assisted laparoscopic radical prostatectomy.\n* Patient is informed about this observational study and has signed the informed consent form.\n\nExclusion Criteria:\n\n* Patient has radiologically of morphologically confirmed prostate cancer metastases before the operation.\n* Patient received neoadjuvant prostate cancer treatment.\n* Patient is set to receive adjuvant treatment.\n* Patient has any contraindications for the operation.",{"count":109,"type":22},500,"10 Years","This prospective observational study aims to evaluate the prognostic significance of early postoperative prostate-specific antigen (PSA) levels in patients undergoing radical prostatectomy for prostate cancer.\n\nNo investigational interventions will be performed. All diagnostic procedures, follow-up assessments, and treatments will be conducted in accordance with standard clinical practice and established prostate cancer management guidelines. Participation in the study will not influence treatment decisions.",[113,85,114,39,115],"Prostate Cancer (Post Prostatectomy)","Prostate Cancer (Diagnosis)","Radical Prostatectomy",[89,117,118,119],"persistent prostate-specific antigen","prostate-specific antigen","radical prostatectomy","2026-04-01",{"date":122,"type":64},"2026-04-08",{"date":124,"type":64},"2024-01-22",{"date":126,"type":22},"2039-07",{"name":128,"class":71},"Lithuanian University of Health Sciences",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":136,"minAge":4,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":72},"100573605","a-cluster-package-intervention-to-promote-an-evidence-based-use-of-psa-tests-in-general-practice-100573605","NCT06748456","A Cluster Package Intervention to Promote an Evidence-based Use of PSA-tests in General Practice","Development and Evaluation of a Cluster Package Intervention to Promote an Evidence-based Use of PSA-tests in General Practice: A Cluster Randomized Trial","Inclusion Criteria:\n\n* Quality clusters with a cluster coordinator\n* Quality clusters willing to participate in a cluster meeting with PSA as a theme in 2025.\n\nExclusion Criteria:\n\n* Quality clusters who already planned their cluster meetings in 2025.\n* Quality clusters unwilling to await allocation before planning their cluster meetings in 2025.\n* Quality clusters participating in the pilot study","ALL",{"count":81,"type":22},[25],"It is widely acknowledged that prostate specific antigen (PSA) testing can lead to false-positives, overdiagnosis and overtreatment of prostate cancer. The current national clinical guidelines only recommend the test to a small group of patients and does not recommend neither systematic nor opportunistic screening for prostate cancer with the test.\n\nThe aim of this cluster randomized trial is to evaluate the effectiveness of a complex intervention aimed at improving the use of evidence based practice when using prostate specific antigen tests in general practice.\n\nThe complex intervention in this study is a so called cluster package which is meeting material to a quality cluster meeting as almost every general practitioner is a member of a quality cluster. Therefore, the investigators have developed a cluster package aimed at promoting an evidence-based use of the prostate specific antigen test to general practitioners.",[28,141,39],"Evidence Based Medicine",[143,28,144,145,146],"PSA-test","Evidence based medicine","Quality clusters","General practice","2024-12-20",{"date":149,"type":64},"2024-12-27",{"date":151,"type":64},"2024-09-09",{"date":153,"type":22},"2026-01-01",{"name":155,"class":71},"University of Copenhagen",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":136,"minAge":4,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":174,"locationsCount":72},"100562827","prognostic-study-of-prostate-cancer-via-dynamic-change-of-psa-in-peritoneal-drainage-fluid-after-radical-prostatectomy-100562827","NCT06608225","Prognostic Study of Prostate Cancer Via Dynamic Change of PSA in Peritoneal Drainage Fluid After Radical Prostatectomy","Inclusion Criteria:\n\n* Prostate cancer patients treated with radical prostatectomy\n\nExclusion Criteria:\n\n* 1\\. Received neoadjuvant endocrine\u002Fchemotherapy before surgery;\n* 2\\. Urine leakage after surgery (positive creatinine test of drainage fluid).",{"count":163,"type":22},100,"This study investigates the prognostic value of dynamic changes in Prostate-Specific Antigen (PSA) levels found in the peritoneal drainage fluid after radical prostatectomy. Prostate cancer is one of the most common cancers in men, and radical prostatectomy is a standard treatment. While PSA levels in the blood are commonly used as a marker for diagnosis, this study focuses on the significance of PSA levels in the prognosis of prostate cancer. The findings may provide insights into improved post-surgical monitoring and more tailored therapeutic strategies for prostate cancer patients.",[166,167],"Prostatic Neoplasms","Prostate-Specific Antigen","2024-11-26",{"date":170,"type":64},"2024-11-29",{"date":172,"type":22},"2024-12-01",{"date":172,"type":22},{"name":175,"class":71},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine"]